Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/velpatasvir plus ribavirin for chronic hepatitis C with Child-Pugh-Turcotte class C cirrhosis
2016-003066-10Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of velpatasvir and ribavirin in chronic hepatitis C (CHC), sponsored by Gilead Sciences. Primary endpoint: SVR12. Started Dec 2017; status: completed.
02
Drugs
velpatasvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-003066-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003066-10.